Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 6/2010

01-06-2010 | Original Article

Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment

Authors: Thaís Helena Gasparoto, Tatiana Salles de Souza Malaspina, Luciana Benevides, Edgard Jose Franco de Melo Jr, Maria Renata Sales Nogueira Costa, José Humberto Damante, Maura Rosane Valério Ikoma, Gustavo Pompermaier Garlet, Karen Angélica Cavassani, João Santana da Silva, Ana Paula Campanelli

Published in: Cancer Immunology, Immunotherapy | Issue 6/2010

Login to get access

Abstract

Oral squamous cell carcinoma (OSCC) is a cancerous lesion with high incidence worldwide. The immunoregulatory events leading to OSCC persistence remain to be elucidated. Our hypothesis is that regulatory T cells (Tregs) are important to obstruct antitumor immune responses in patients with OSCC. In the present study, we investigated the frequency, phenotype, and activity of Tregs from blood and lesions of patients with OSCC. Our data showed that >80% of CD4+CD25+ T cells isolated from PBMC and tumor sites express FoxP3. Also, these cells express surface Treg markers, such as GITR, CD45RO, CD69, LAP, CTLA-4, CCR4, and IL-10. Purified CD4+CD25+ T cells exhibited stronger suppressive activity inhibiting allogeneic T-cell proliferation and IFN-γ production when compared with CD4+CD25+ T cells isolated from healthy individuals. Interestingly, approximately 25% of CD4+CD25 T cells of PBMC from patients also expressed FoxP3 and, although these cells weakly suppress allogeneic T cells proliferative response, they inhibited IFN-γ and induced IL-10 and TGF-β secretion in these co-cultures. Thus, our data show that Treg cells are present in OSCC lesions and PBMC, and these cells appear to suppress immune responses both systemically and in the tumor microenvironment.
Literature
1.
go back to reference Shevach M (2001) Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 193:F41–F46CrossRefPubMed Shevach M (2001) Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 193:F41–F46CrossRefPubMed
2.
go back to reference Curotto de Lafaille MA, Lafaille JJ (2009) Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30:626–635CrossRefPubMed Curotto de Lafaille MA, Lafaille JJ (2009) Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30:626–635CrossRefPubMed
3.
go back to reference Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6:345–352CrossRefPubMed Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6:345–352CrossRefPubMed
4.
go back to reference Liyanage UK, Moore TT, Joo HG et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756–2761PubMed Liyanage UK, Moore TT, Joo HG et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756–2761PubMed
5.
go back to reference Liu L, Yao J, Ding Q, Huang S (2006) CD4+CD25high regulatory cells in peripheral blood of NSCLC patients. J Huazhong Univ Sci Technol Med Sci 26:548–551CrossRefPubMed Liu L, Yao J, Ding Q, Huang S (2006) CD4+CD25high regulatory cells in peripheral blood of NSCLC patients. J Huazhong Univ Sci Technol Med Sci 26:548–551CrossRefPubMed
6.
go back to reference Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T (2005) CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 14:1269–1273PubMed Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T (2005) CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 14:1269–1273PubMed
7.
go back to reference Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A (2003) CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98:1089–1099CrossRefPubMed Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A (2003) CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98:1089–1099CrossRefPubMed
8.
go back to reference Matsuura K, Yamaguchi Y, Ueno H, Osaki A, Arihiro K, Toge T (2006) Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer 106:1227–1236CrossRefPubMed Matsuura K, Yamaguchi Y, Ueno H, Osaki A, Arihiro K, Toge T (2006) Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer 106:1227–1236CrossRefPubMed
9.
go back to reference Badoual C, Hans S, Rodriguez J et al (2006) Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12:465–472CrossRefPubMed Badoual C, Hans S, Rodriguez J et al (2006) Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12:465–472CrossRefPubMed
10.
go back to reference Fox SB, Launchbury R, Bates GJ et al (2007) The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2 alpha but not HIF-1alpha. Prostate 67:623–629CrossRefPubMed Fox SB, Launchbury R, Bates GJ et al (2007) The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2 alpha but not HIF-1alpha. Prostate 67:623–629CrossRefPubMed
11.
go back to reference Bates GJ, Fox SB, Han C et al (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24:5373–5380CrossRefPubMed Bates GJ, Fox SB, Han C et al (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24:5373–5380CrossRefPubMed
12.
13.
go back to reference Sakaguchi S, Sakaguchi N, Shimizu J et al (2001) Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18–32CrossRefPubMed Sakaguchi S, Sakaguchi N, Shimizu J et al (2001) Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18–32CrossRefPubMed
14.
go back to reference Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL (2007) A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13:4345–4354CrossRefPubMed Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL (2007) A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13:4345–4354CrossRefPubMed
15.
go back to reference Valzasina B, Piconese S, Guiducci C, Colombo MP (2006) Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25− lymphocytes is thymus and proliferation independent. Cancer Res 66:4488–4495CrossRefPubMed Valzasina B, Piconese S, Guiducci C, Colombo MP (2006) Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25 lymphocytes is thymus and proliferation independent. Cancer Res 66:4488–4495CrossRefPubMed
16.
go back to reference Akbar AN, Taams LS, Salmon M, Vukmanovic-Stejic M (2003) The peripheral generation of CD4+CD25+ regulatory T cells. Immunology 109:319–325CrossRefPubMed Akbar AN, Taams LS, Salmon M, Vukmanovic-Stejic M (2003) The peripheral generation of CD4+CD25+ regulatory T cells. Immunology 109:319–325CrossRefPubMed
17.
go back to reference Akbar AN, Vukmanovic-Stejic M, Taams LS, Macallan DC (2007) The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery. Nat Rev Immunol 7:231–237CrossRefPubMed Akbar AN, Vukmanovic-Stejic M, Taams LS, Macallan DC (2007) The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery. Nat Rev Immunol 7:231–237CrossRefPubMed
18.
go back to reference Campanelli AP, Roselino AM, Cavassani KA et al (2006) CD4+CD25+ T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells. J Infect Dis 193:1313–1322CrossRefPubMed Campanelli AP, Roselino AM, Cavassani KA et al (2006) CD4+CD25+ T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells. J Infect Dis 193:1313–1322CrossRefPubMed
20.
go back to reference Lissoni P, Brivio F, Fumagalli L et al (2009) Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients. Anticancer Res 29:1847–1852PubMed Lissoni P, Brivio F, Fumagalli L et al (2009) Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients. Anticancer Res 29:1847–1852PubMed
21.
go back to reference Cesana GC, DeRaffaele G, Cohen S et al (2006) Characterization of CD4+CD25+ regulatory T-cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24:1169–1177CrossRefPubMed Cesana GC, DeRaffaele G, Cohen S et al (2006) Characterization of CD4+CD25+ regulatory T-cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24:1169–1177CrossRefPubMed
22.
go back to reference Wang Z, Hong J, Sun W et al (2006) Role of IFN-gamma in induction of Foxp3 and conversion of CD4+CD25− T cells to CD4+ Tregs. J Clin Invest 116:2434–2441PubMed Wang Z, Hong J, Sun W et al (2006) Role of IFN-gamma in induction of Foxp3 and conversion of CD4+CD25 T cells to CD4+ Tregs. J Clin Invest 116:2434–2441PubMed
23.
24.
go back to reference Clarke SL, Betts GJ, Plant A et al (2006) CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE 1:e129CrossRefPubMed Clarke SL, Betts GJ, Plant A et al (2006) CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE 1:e129CrossRefPubMed
25.
go back to reference Tokuno K, Hazama S, Yoshino S, Yoshida S, Oka M (2009) Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer. Anticancer Res 29:1527–1532PubMed Tokuno K, Hazama S, Yoshino S, Yoshida S, Oka M (2009) Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer. Anticancer Res 29:1527–1532PubMed
26.
go back to reference Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL (2005) Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92:913–920CrossRefPubMed Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL (2005) Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92:913–920CrossRefPubMed
27.
go back to reference Schwarz S, Butz M, Morsczeck C, Reichert TE, Driemel O (2008) Increased number of CD25 FoxP3 regulatory T cells in oral squamous cell carcinomas detected by chromogenic immunohistochemical double staining. J Oral Pathol Med 37:485–489PubMedCrossRef Schwarz S, Butz M, Morsczeck C, Reichert TE, Driemel O (2008) Increased number of CD25 FoxP3 regulatory T cells in oral squamous cell carcinomas detected by chromogenic immunohistochemical double staining. J Oral Pathol Med 37:485–489PubMedCrossRef
28.
go back to reference Strauss L, Bergmann C, Johnson J, Whiteside TL (2006) Functional CD4+CD25highFoxp3+ T cells in the circulation of patients with head and neck squamous cell carcinoma (HNSCC) and correlation with advanced disease. Arch Otolaryngol Head Neck Surg 132:883–884CrossRef Strauss L, Bergmann C, Johnson J, Whiteside TL (2006) Functional CD4+CD25highFoxp3+ T cells in the circulation of patients with head and neck squamous cell carcinoma (HNSCC) and correlation with advanced disease. Arch Otolaryngol Head Neck Surg 132:883–884CrossRef
Metadata
Title
Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment
Authors
Thaís Helena Gasparoto
Tatiana Salles de Souza Malaspina
Luciana Benevides
Edgard Jose Franco de Melo Jr
Maria Renata Sales Nogueira Costa
José Humberto Damante
Maura Rosane Valério Ikoma
Gustavo Pompermaier Garlet
Karen Angélica Cavassani
João Santana da Silva
Ana Paula Campanelli
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 6/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0803-7

Other articles of this Issue 6/2010

Cancer Immunology, Immunotherapy 6/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine